Side-by-side · Research reference

TesamorelinvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship27/68 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Tesamorelin

GHRH Analogue · FDA-Approved

2 mgDaily doseEGRIFTA® (tesamorelin for inje 2010

15–20%VAT reductionFalutz 2010

~26 minHalf-lifeEGRIFTA® (tesamorelin for inje 2010

SQ · Abdomen · Once Daily

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Tesamorelin

VIP

Primary target

Hypothalamic GHRH receptorsEGRIFTA® (tesamorelin for inje 2010

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

GHRH → Pituitary GH release → Liver IGF-1 synthesisFalutz 2007

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Increased GH pulsatility, elevated IGF-1, lipolysis of visceral adipose tissueFalutz 2010

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

Yes — physiological pulsatility preserved

Yes — exogenous VIP acts as physiological agonist

Origin

Synthetic 44-AA GHRH analogue with trans-3-hexenoic-acid modification for stabilityEGRIFTA® (tesamorelin for inje 2010

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

~50% after 26 wks (non-neutralising in most)Sévigny 2018

—

02Dosage Protocols

Parameter

Tesamorelin

VIP

Standard dose

2 mg / dayEGRIFTA® (tesamorelin for inje 2010

FDA-approved protocol.

—

Frequency

Once daily (morning or pre-sleep)

Aligns with natural GH pulse.

—

Lower / starter dose

1 mg / dayFalutz 2010

1 mg still produces significant IGF-1 elevation.

—

Evidence basis

RCT / FDA-approvedFalutz 2007 Falutz 2010

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Duration

12–52 weeks

VAT returns within months of stopping.

—

Reconstitution

Sterile water per labeling

Preserved at 2–8 °C after reconstitution.

Lyophilized powder reconstituted with sterile diluent per protocol

Timing

Empty stomach, pre-sleep preferred

—

Half-life

~26 min (plasma)EGRIFTA® (tesamorelin for inje 2010

Modified vs native GHRH (7 min t½).

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

03Metabolic / Fat Loss Evidence

Parameter

Tesamorelin

VIP

Primary fat target

Visceral adipose tissue (VAT) — abdominal

—

Quantified reduction

15–20% VAT ↓Falutz 2010

By CT at 26 weeks (Falutz et al., NEJM).

—

IGF-1 impact

+66 ng/mL (2 mg dose) · +81% mean elevationFalutz 2007

—

Effect on lean mass

Modest lean mass preservation / slight increase

—

Insulin sensitivity

Neutral to slight impairment (monitor HbA1c)Clarke 2018

—

Triglycerides

Significant TG reduction noted in Phase 3Falutz 2010

—

Glucose metabolism

Generally neutral; 4.5% HbA1c elevation riskClarke 2018

—

Effect reversibility

VAT returns within months of stopping

—

Key publication

Falutz et al. NEJM 2007 · Falutz JCEM 2010 · FDA approval 2010Falutz 2007 Falutz 2010 EGRIFTA® (tesamorelin for inje 2010

—

04Side Effects & Safety

Parameter

Tesamorelin

VIP

Injection site reaction

Erythema, pruritus, redness (common)

—

Fluid retention / Edema

Peripheral edema, arthralgia, carpal tunnel (GH-axis effect)

—

Glucose intolerance

HbA1c ↑ in 4.5% vs 1.3% placebo; HbA1c ≥6.5% hazard OR 3.3Clarke 2018

—

IGF-1 elevation

Dose-dependent; supraphysiological levels = discontinue

—

Cancer risk

Contraindicated in active malignancy (GH/IGF-1 axis); theoretical tumour growth riskEGRIFTA® (tesamorelin for inje 2010

—

Antibody formation

~50% at 26 weeks; non-neutralising in most; rare hypersensitivity (<1%)Sévigny 2018

—

GI symptoms

Nausea, diarrhea (mild, transient)

Nausea, diarrhea (VIP is endogenous GI peptide)

Pregnancy / OB

ContraindicatedEGRIFTA® (tesamorelin for inje 2010

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Tesamorelin

·Active malignancy or history of treated cancer
·Pregnancy
·Hypersensitivity to tesamorelin or mannitol
·Disruption of hypothalamic-pituitary axis (trauma, tumour, radiation)

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Tesamorelin

·Untreated diabetes (monitor HbA1c)
·Severe carpal tunnel syndrome
·Acute critical illness

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Tesamorelin

VIP

1. Reconstitution

Add 2.1 mL sterile water to 2 mg lyophilised vial. Roll gently — do not shake. Solution should be clear.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Injection site

Subcutaneous — abdomen preferred. Rotate sites (avoid same spot within 2 cm). Avoid navel and waistband area.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Once daily. Preferred: evening, 2–3 hrs post-meal, before sleep — aligns with natural GH secretion pulse.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 21 days.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Needle

27–31G, 4–8 mm insulin syringe. Pinch skin, 45° angle for lean individuals.

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.

06Stack Synergy

Tesamorelin

+ Ipamorelin

Strong

View Ipamorelin →

Tesamorelin (GHRH analogue) and ipamorelin (GHRP / ghrelin mimetic) act on two distinct receptor systems to amplify GH release synergistically — GHRH receptor + ghrelin receptor. This dual-axis stimulation produces a more robust, sustained GH pulse than either alone while maintaining physiological pulsatility. Ipamorelin is highly selective with minimal cortisol or prolactin elevation, making it the preferred GHRP pairing.

Tesamorelin: 2 mg SQ · evening
Ipamorelin: 200–300 mcg SQ · same injection
Frequency: Once daily, pre-sleep
Primary benefit: Maximal GH pulsatility, fat loss, recovery, sleep quality

Raun 1998

VIP

— no documented stacks